Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Average (2021 - 2023)

Historic Equity Average for Cullinan Therapeutics (CGEM) over the last 3 years, with Q3 2023 value amounting to $484.2 million.

  • Cullinan Therapeutics' Equity Average fell 1867.36% to $484.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $484.2 million, marking a year-over-year decrease of 1867.36%. This contributed to the annual value of $480.2 million for FY2022, which is 5349.55% up from last year.
  • As of Q3 2023, Cullinan Therapeutics' Equity Average stood at $484.2 million, which was down 1867.36% from $492.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' Equity Average's 5-year high stood at $595.4 million during Q3 2022, with a 5-year trough of $335.0 million in Q1 2021.
  • Its 3-year average for Equity Average is $478.6 million, with a median of $484.2 million in 2023.
  • In the last 5 years, Cullinan Therapeutics' Equity Average soared by 3171.77% in 2022 and then crashed by 1867.36% in 2023.
  • Quarter analysis of 3 years shows Cullinan Therapeutics' Equity Average stood at $435.4 million in 2021, then rose by 28.74% to $560.6 million in 2022, then decreased by 13.63% to $484.2 million in 2023.
  • Its last three reported values are $484.2 million in Q3 2023, $492.6 million for Q2 2023, and $510.3 million during Q1 2023.